GANX
Gain Therapeutics, Inc.
$1.91
-0.08 (-4.02%)
At close · Jul 2
Market Cap
$81.47M
Shares
42,654,038
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.91
Open$1.97
Day$1.89–2.03
52W$1.41–4.34
Avg vol 30d846K
Short int3.9M · 9.1% float · 6.1d
Short vol43%
Last earningsMay 11, 2026
DataMar 2021–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−13% below
+
Price vs 50-day avg
+5% above
◦
RSI (14)
55 · neutral
+
MACD trend
positive
◦
52-week position
17% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $2 › 200d $2 — 200d above 50d
−
Institutional flow
-14% holders QoQ · +9 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
9.07% of float · ▲ +21.0% MoM · 6.1 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
42 holders — mid 3-yr range
Fundamentals
Fair
−
Revenue growth
−61% Y/Y
+
EPS growth
+31% Y/Y
−
Free cash flow
$-18.6M
+
Balance sheet
net cash $20.4M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−13% below
Bearish
Price vs 50-day avg
+5% above
Bullish
RSI (14)
55 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
17% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.07% of float · ▲ +21.0% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 17%
52-wk high $4
vs 200-day avg -13%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GANX
this stock
Gain Therapeutics, Inc.
|
$81.47M | -40.7% | -60.6% | — | 9.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GANX | +11.1% | +6.7% | -21.7% | -5.9% | -40.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +9.6% | +8.0% | -29.7% | -5.6% | -49.9% |